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period: In the period of four as well as eigth – weeks course of treatment with imiqui-
mod 5% cream, therapy resulted in signiﬁcantly higher chance of achieving complete 
clearance. Patients treated with imiquimod more frequently achieved clearance level 
higher than 75% of baseline actinic keratoses compared with the subject in vehicle 
group. Adverse events were more frequently recorded within the group of subjects 
who received imiquimod in comparison with vehicle group. The chance of experienc-
ing local skin reaction such as erythema, ﬂaking/scaling/dryness, scabbing/crusting, 
oedema, vesicles, erosin/ulceration was signiﬁcantly higher in experimental group. 
Imiquimod ﬁve percent cream versus vehicle in long time period: Imiquimod 5% cream 
used 3 times a week for 24 weeks was an effective treatment for actinic keratosis 
measured by the probability of achieving complete clearance and partial clearance rate 
(more than 75% reduction in baseline lesions). Frequency of adverse events and local 
skin reactions was higher during the imiquimod treatment in comparison with 
placebo. Imiquimod ﬁve percent cream versus vehicle in patient with solid organ 
transplants: Treatment with imiquimod 5% cream for 24 weeks in kidney, heart and 
liver transplant patients resulted in signiﬁcantly higher probability of achieving com-
plete and partial clearance rates of actinic keratoses. There were no signiﬁcant differ-
ences in incidence of adverse events between groups. CONCLUSIONS: Imiquimod 
ﬁve percent cream appears to be effective and safe alternative therapy for the treatment 
of actinic keratoses.
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OBJECTIVES: The aim of this study was to compare the 18 months Nd : Yag laser 
incidence rate of two multifocal intra-ocular lenses, ReSTOR® and Acrilisa®, implanted 
by a single surgeon following his usual practice. METHODS: This retrospective study 
was based on all patients implanted with a ReSTOR® or Acrilisa® multi-focal lens 
since Q3–2004 at one site. All patients with either cataract or clear lens were operated 
by the same surgeon. Medical data were obtained from patient charts. 18-months post 
surgical data were obtained from the surgeon’s medical ﬁles and from other ophthal-
mologists, if involved in post-surgical care. Time to Nd : Yag laser analysis was carried 
out using Kaplan-Meier survival curves. Imbalance on confounding variables was 
adjusted with a Cox model. RESULTS: Eighty patients (160 eyes) were bilaterally 
implanted with ReSTOR® and 76 (152 eyes) with Acrilisa®. Patients with ReSTOR® 
were more often male (52.5% versus 30.7%; P  0.01) and younger (63.1 versus 65.8; 
P  0.01). After one year of follow-up, 3.6% of the ReSTOR® eyes had Nd : Yag laser 
versus 6.8% of the Acrilisa® eyes. After 18 months, the incidence rates were 4.6% 
and 26.0%, respectively (P  0.0001). Age was weakly associated with Nd : Yag laser 
(p  0.09). Eyes with Acrilisa® had 5.62 [2.64–14.02; P  0.0002] more chances to 
have Nd : Yag laser than ReSTOR®. This persisted after adjusting on age [Hazard 
Ratio: 6.61; 2.61–16.76; P  0.0001]. CONCLUSIONS: This analysis conducted at 
18 months suggested that following usual surgical practice, ReSTOR® eyes had sig-
niﬁcantly less capsulotomy than those implanted with Acrilisa®. Young population 
were slightly more exposed at Nd : Yag laser. Analyses at two and three years will be 
required to conﬁrm these ﬁndings.
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OBJECTIVES: To assess the association of conjunctival hyperaemia with the ﬁxed 
combinations of latanoprost/timolol (LT/TM) and bimatoprost/timolol (BM/TM) in 
the treatment of ocular hypertension or glaucoma using a systematic review and meta-
analyisis of randomized clinical trials (RCTs). METHODS: A systematic search for 
RCTs published between 2000 and 2009 was conducted in Medline, Embase and 
Controlled Trials Register databases. The outcome measured was the appearance of 
conjunctival hyperaemia in studies comparing the use of either LT/TM or BM/TM 
versus different therapeutic options. Statistical analysis was performed including the 
calculation of odds ratio (OR) and its respective conﬁdence interval, along with the 
inter-trial statistical heterogeneity. A sensitivity analysis was also carried out. 
RESULTS: A total of 16 RCTs comparing LT/TM versus distinct therapeutic alterna-
tives and 5 CT comparing BM/TM versus different therapeutic options fulﬁlled criteria 
to be included in the meta-analysis. Although heterogeneity of both comparisons was 
not very high in both the LT/TM group (Q  24.47; p  0.057; I2  38.7 %) and 
the BM/TM group (Q  5.19; p  0.268; I2  22.94 %), the estimation of the OR by 
the random effects model was considered the most appropriate. According to this 
model the ﬁnal OR for the LT/TM group was 0.56 (IC95%: 0.37–0.83), p  0.05 and 
for the BT/TM group the OR was 0.94 (IC95%: 0.66–1.34), p  0.05. In the sensitivity 
analysis performed, none of the RCTs included in this meta-analysis had an important 
effect in the global estimation of OR. CONCLUSIONS: According to available data, 
the use of LT/TM is associated with a signiﬁcant reduction in the development of 
conjunctival hyperaemia versus the comparators used in the RCTs, whereas the use 
of BM/TM produces a conjunctival hyperaemia rate similar to its comparators.
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OBJECTIVES: To date, quantitative risk beneﬁt has mainly involved the translation 
of Cost-Effectiveness techniques or utility adjusted epidemiological statistics. We aim 
to describe how Discrete Event Simulation “DES” offers the possibility of modelling 
the occurrence of several adverse events and beneﬁcial events simultaneously whilst 
accounting for competing events. METHODS: Firstly, a longitudinal patient database 
is used to identify the target patient population. Secondly, incidence rates for the out-
comes are calculated from the entire database, thereby providing the necessary granu-
larity in terms of the predictive factors for the outcomes. The annual probability for 
each outcome is then assigned to each patient in the cohort and DES generates time 
to each event. Thereby the expected events for an unexposed patient cohort is created 
to which relative risks are applied to model drug exposure. An example using glau-
coma patients is presented using data from The Health Improvement Network. 
RESULTS: We obtained data on 17,652 glaucoma patients who were known to be 
receiving glaucoma therapy at January 1, 2007. Patients were characterised according 
to the principal determinants of the outcomes (heart failure, asthma/COPD exacerba-
tion). The same database provided general population incidence rates for the outcomes 
which were assigned to each patient according to their characteristics. National sta-
tistics provided death rates. The expected events over one year for a cohort of 10,000 
glaucoma patients were: HF  95; asthma/COPD  143; deaths  605. CONCLU-
SIONS: These expected numbers represent the occurrence of events in the natural 
history cohort. They were obtained by summing the outcome probabilities across the 
patient group. They do, however, represent the ﬁrst step in creating a comprehensive 
method for risk-beneﬁt quantiﬁcation via DES and large patient databases; beneﬁt can 
be modelled if expressed as the occurrence of an event. The method will need to 
incorporate uncertainty in all the input parameters and to update the probabilities 
after an event has occurred.
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OBJECTIVES: Estimation of cost-of-illness (COI) of leg ulcers in two German cross-
sectional studies using different methodical approaches. METHODS: A direct and an 
indirect method for cost estimation were utilized. In a nationwide cross-sectional study 
in 33 specialized dermatological, surgical and general-medical wound centres, resource 
consumption and associated costs of venous leg ulcer(s) were collected directly from 
physicians and patients. In a second cross-sectional regional study, involving 147 
institutions (hospitals, residencies, nursing services, dermatological ofﬁces, services for 
homeless and addictives) treating patients with ulcus cruris, resource consumption and 
associated costs were inferred from history, wound condition and actual/previous 
treatments based on standardized cost categories. Main economic parameters in both 
studies were direct, indirect and intangible costs (health related quality of life, HRQoL) 
from the societal perspective. RESULTS: The national study enrolled n  218 patients 
with a mean age of 69.8 years (regional study: n  502, 71 years). Wounds existed 
for 7 (regional 9) years on average. The mean total COI per year and patient was 
a9,569 (a10,624). While direct costs summed up to a8658 (a9851), indirect costs were 
much lower a911 (a772). Of direct costs, a7631 (a9122) were covered by the Statutory 
Health Insurances (SHI) and a1027 (a730) by the patients. For SHI, major cost factors 
were inpatient costs, non-drug treatments and physicians/nurses fees. Moreover, clini-
cal predictors such as wound size, number and duration as well as wound etiology 
and characteristics of care (quality, support) were identiﬁed. All patients were severely 
impaired in their HRQoL, implying a high burden of disease and relevant intangible 
costs. CONCLUSIONS: Chronic leg ulcers generate highly relevant COI. Despite dif-
ferent recruitment and cost estimation methods, both studies resulted in comparable 
direct, indirect and intangible costs; observed differences can be attributed to sample 
characteristics. The results point to early and qualiﬁed disease management in all 
related health services areas.
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OBJECTIVES: To estimate the direct and indirect costs of occupational severe chronic 
hand eczema (OSCHE) in patients refractory to topical corticosteroids from the per-
spective of employer’s mutual insurance companies (EMIC) in Spain. METHODS: An 
employer’s mutual insurance company in Spain usually covers 75% of salaries and 
100% of medical treatments of patients on occupational sick leave. A decision analytic 
